Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Placebo, Metformin, Sulphonylruea; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 37
States / cities: Huntsville, Alabama • Little Rock, Alaska • Phoenix, Arizona + 34 more

Conditions: Healthy Volunteer
Interventions: BIIB145, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hepatitis B
Interventions: TDF, FTC/TDF, TDF Placebo, FTC/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Bradenton, Florida • Flushing, New York • Philadelphia, Pennsylvania

Conditions: Depression
Interventions: Diazoxide, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity
Interventions: K-757 120 mg BID and K-833 100 mg BID, K-757 120 mg BID and matching placebo to K-833, Matching placebo to K-757 and matching placebo to K-833; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 22
States / cities: San Diego, California • Stockbridge, Georgia • Topeka, Kansas + 19 more

Conditions: Coronary Artery Disease
Interventions: Prasugrel, Clopidogrel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: MEDI6012 40 mg, Placebo, MEDI6012 120 mg, MEDI6012 300 mg, Placebo IV Push, MEDI6012 IV Push; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 60 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 4
States / cities: Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 1 more

Conditions: COVID-19
Interventions: Hydroxychloroquine, Placebo oral tablet; Drug
Lead sponsor: Adrian Hernandez; Other
Eligibility: 18 Years and older
Enrollment: 1,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 34
States / cities: Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more

Conditions: Alzheimer's Disease, Hypertension
Interventions: Ramipril, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Endothelial Dysfunction
Interventions: Climara, Placebo patch, Resveratrol, Placebo; Drug · Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cystic Fibrosis
Interventions: VX-659/TEZ/IVA, TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 28
States / cities: Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 25 more

Conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma, Skin Cancer, Anxiety
Interventions: Randomized Midazolam, Placebo, Local Anesthesia, Prospective Midazolam; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Menopause
Interventions: Paroxetine, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Insomnia
Interventions: Suvorexant, Placebo; Drug
Lead sponsor: Burdick, Daniel, M.D.; Individual
Eligibility: 30 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Prolonged QTc Interval
Interventions: Estetrol 20 mg, Estetrol 100 mg, Placebo, Moxifloxacin 400 mg; Drug
Lead sponsor: Estetra; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Glendale, California + 20 more

Conditions: Healthy Volunteers
Interventions: TAK-105-a, TAK-105-a Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Tempe, Arizona • Las Vegas, Nevada • Austin, Texas

Conditions: Heavy Drinking, HIV, Alcohol Dependence
Interventions: Topiramate, Medical Management, Placebo; Drug · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Hyperaldosteronism
Interventions: Baxdrostat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: San Francisco, California • Farmington, Connecticut • Springfield, Illinois + 11 more

Conditions: Constipation, Diabetes Mellitus, Colonic Transit, Gastric Emptying
Interventions: Pyridostigmine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HCV Infection
Interventions: GS-5885, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Anaheim, California • Cypress, California • National City, California + 10 more

Conditions: Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
Interventions: Naproxen Sodium, Placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Acute Pain
Interventions: Placebo, Naproxen, Pregabalin; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions: EDP-978, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease

Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's

The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery

Study of Paxil Use in Menopausal Women

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

Effect of Estetrol Monohydrate (E4) on QTc Interval

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

A Study of TAK-105 in Healthy Adults

Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers

Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

Use of Pyridostigmine for Constipation in Diabetics

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Mechanistic Characterization of Uterine Pain

Human Experimental Models of Pain (HEMP)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults